Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets

Author(s):  Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'

Issue:  Jul/Aug 2012 - Volume 16, Number 4
View All Articles in Issue

Page(s):  342-346

Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 1
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 2
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 3
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 4
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 5

Download in electronic PDF format for $75

Abstract:  The purpose of this study was to formulate a 25-mg atenolol capsule starting from a commercial 100-mg atenolol tablet, given the fact that this strength is not available in Palestine and also because 50-mg atenolol tablets failed the splitting uniformity test of the European Pharmacopoeia, and to evaluate the chemical stability and dissolution behavior of the obtained capsules so as to ensure a high-quality product. A high-performance liquid chromatographic system was used for the analysis and quantification of atenolol in the samples studied. Samples of atenolol for analysis were prepared as reported by the United States Pharmacopeia monograph. Disintegration and dissolution tests were performed according to the United States Pharmacopeia. The high-performance liquid chromatography assay indicated that the 25-mg atenolol capsules were stable for four months when stored at ambient temperature conditions. The disintegration time for all atenolol capsules was within the United States Pharmacopeia limits of 15 minutes. Atenolol release profile showed that approximately 90% of atenolol dissolved after 10 minutes. This study is important for patients who need to take one half of a 50-mg tablet, but for whom the splitting process doesn’t give equal halves, and also for modifying the dose for patients with renal or hepatic problems. Therefore, it is possible for the community pharmacist to crush atenolol 100-mg tablets and refill them in new capsules with each containing a precise amount of atenolol, calculated according to body surface area and kidney and liver functions without affecting the chemical stability of the active ingredient nor its dissolution profile and also have a cost effective dosage form.

Related Keywords: formulation, atenolol, beta-blocker, hypertension, high blood pressure, arrhythmias, angina pectoris, myocardial infarction, heart attack, stability

Related Categories: FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, QUALITY CONTROL, CARDIOLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets
Zaid Abdel Naser
, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
Jul/Aug 2012
Pg. 342-346

Atenolol 25-, 50-, or 100-mg Capsules
Allen Loyd V Jr
Jan/Feb 2015
Pg. 60

Atenolol 1 mg/mL or 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
May/Jun 2018
Pg. 233

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin
, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
May/Jun 2003
Pg. 233-239

Short-Term Stability of Atenolol in Oral Liquid Formulations
Patel Dipali
, Doshi Dharmesh H, Desai Archana
Nov/Dec 1997
Pg. 437-439

Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC
, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2016
Pg. 167-174

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III
, Everett Eric, Chamberlain Tyler
May/Jun 2020
Pg. 194-197

Stability of Propranolol Hydrochloride in SyrSpend SF
Geiger Christine M
, Voudrie Mark A II, Sorenson Bridget
Nov/Dec 2012
Pg. 513-515

Metoprolol Tartrate 1-mg/mL Injection
Allen Loyd V Jr
Jul/Aug 2013
Pg. 333

Nifedipine 4.mg/mL in SyrSpend SF pH4 Cherry Flavored
Allen Loyd V Jr
Jul/Aug 2021
Pg. 327

A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
Sep/Oct 2022
Pg. 364-368

Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules
Fortner Jeff
, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa
Sep/Oct 2015
Pg. 414-419

Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations
Sidhom Madiha B
, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L
Sep/Oct 2005
Pg. 402-406

Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding
Garg Sanjay
, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
May/Jun 2009
Pg. 250-253

Coenzyme Q10 Supplementation in the Treatment of Heart Disease
Bramwell Bethany L
Mar/Apr 2010
Pg. 108-111

Labetalol 50-mg Capsules
Allen Loyd V Jr
May/Jun 2013
Pg. 233

Formulation and Stability of Solutions
Akers Michael J
Jan/Feb 2016
Pg. 41-45

A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding
Rush Steven D
, Vernak Charlene, Zhao Fang
Jan/Feb 2017
Pg. 83-87

Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt
Graves Richard
, Phan Kelly V, Bostanian Levon A, Mandal Tarun K, Pramar Yashoda V
Jul/Aug 2017
Pg. 334-338

Return to Top